Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabinoid oils are **pharmaceutical-grade, botanically sourced cannabinoid oil formulations containing tetrahydrocannabinol and cannabidiol** being developed by Ethicann Pharmaceuticals. Based on the provided context, this is a plant-derived cannabinoid combination product rather than a synthetic small molecule, intended for neurologic and pain indications including **multiple sclerosis-related spasticity, adult focal epilepsy, and cancer pain**. Its pharmacology is expected to derive primarily from mixed cannabinoid receptor modulation by THC together with the broader anticonvulsant and neuromodulatory effects of CBD, although the exact product composition, ratio, dosage form, and administration details were not specified in the source excerpt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabinoid oils.